Cargando…

Natural history of bleeding and characteristics of early bleeders among warfarin initiators – a cohort study in Finland

AIMS: The demand for oral anticoagulant therapy will continue to increase in the future along with the aging of the population. This study aimed to determine the rate of bleeding requiring hospitalization and to characterize early bleeders among persons initiating warfarin therapy. Characterization...

Descripción completa

Detalles Bibliográficos
Autores principales: Rikala, Maria, Kastarinen, Helena, Tiittanen, Pekka, Huupponen, Risto, Korhonen, Maarit Jaana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4751892/
https://www.ncbi.nlm.nih.gov/pubmed/26917975
http://dx.doi.org/10.2147/CLEP.S91379
_version_ 1782415646648172544
author Rikala, Maria
Kastarinen, Helena
Tiittanen, Pekka
Huupponen, Risto
Korhonen, Maarit Jaana
author_facet Rikala, Maria
Kastarinen, Helena
Tiittanen, Pekka
Huupponen, Risto
Korhonen, Maarit Jaana
author_sort Rikala, Maria
collection PubMed
description AIMS: The demand for oral anticoagulant therapy will continue to increase in the future along with the aging of the population. This study aimed to determine the rate of bleeding requiring hospitalization and to characterize early bleeders among persons initiating warfarin therapy. Characterization of those most susceptible to early bleeding is important in order to increase the safety of warfarin initiation. PATIENTS AND METHODS: Using data from nationwide health registers, we identified persons initiating warfarin therapy between January 1, 2009 and June 30, 2012, n=101,588, and followed them until hospitalization for bleeding, death, or administrative end of the study (December 31, 2012). We defined early bleeders as persons with a bleeding requiring hospitalization within 30 days since warfarin initiation. RESULTS: The rate of hospitalization for bleeding during a median follow-up of 1.9 years was 2.6% per person-year (95% confidence interval [CI] 2.5%–2.7%), with a peak within the first 30 days of warfarin initiation (6.5% per person-year, 95% CI 6.0%–7.1%). In a multivariable Cox proportional hazards regression analysis, early bleeders were characterized by prior bleeding (<180 days before initiation, hazard ratio [HR] =13.7, 95% CI 10.9–17.1; during 180 days–7 years before initiation, HR =1.48, 95% CI 1.15–1.90), male sex (HR =1.32, 95% CI 1.10–1.57), older age (HR =1.13, 95% CI 1.04–1.22, per 10-year increase), venous thrombosis (HR =1.83, 95% CI 1.44–2.34), pulmonary embolism (HR =1.46, 95% CI 1.11–1.91), alcohol abuse (HR =1.59, 95% CI 1.08–2.35), rheumatic disease (HR =1.40, 95% CI 1.07–1.83), and exposure to drugs with dynamic interaction mechanism with warfarin (HR =1.43, 95% CI 1.20–1.71). In age-adjusted models, Charlson comorbidity index and number of drugs predicted a graded increase in the hazard of early bleeding. CONCLUSION: The rate of hospitalizations for bleeding peaked in the beginning of warfarin therapy. Early bleeders were characterized by venous thrombosis, pulmonary embolism, and factors that increase bleeding risk without affecting the international normalized ratio.
format Online
Article
Text
id pubmed-4751892
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-47518922016-02-25 Natural history of bleeding and characteristics of early bleeders among warfarin initiators – a cohort study in Finland Rikala, Maria Kastarinen, Helena Tiittanen, Pekka Huupponen, Risto Korhonen, Maarit Jaana Clin Epidemiol Original Research AIMS: The demand for oral anticoagulant therapy will continue to increase in the future along with the aging of the population. This study aimed to determine the rate of bleeding requiring hospitalization and to characterize early bleeders among persons initiating warfarin therapy. Characterization of those most susceptible to early bleeding is important in order to increase the safety of warfarin initiation. PATIENTS AND METHODS: Using data from nationwide health registers, we identified persons initiating warfarin therapy between January 1, 2009 and June 30, 2012, n=101,588, and followed them until hospitalization for bleeding, death, or administrative end of the study (December 31, 2012). We defined early bleeders as persons with a bleeding requiring hospitalization within 30 days since warfarin initiation. RESULTS: The rate of hospitalization for bleeding during a median follow-up of 1.9 years was 2.6% per person-year (95% confidence interval [CI] 2.5%–2.7%), with a peak within the first 30 days of warfarin initiation (6.5% per person-year, 95% CI 6.0%–7.1%). In a multivariable Cox proportional hazards regression analysis, early bleeders were characterized by prior bleeding (<180 days before initiation, hazard ratio [HR] =13.7, 95% CI 10.9–17.1; during 180 days–7 years before initiation, HR =1.48, 95% CI 1.15–1.90), male sex (HR =1.32, 95% CI 1.10–1.57), older age (HR =1.13, 95% CI 1.04–1.22, per 10-year increase), venous thrombosis (HR =1.83, 95% CI 1.44–2.34), pulmonary embolism (HR =1.46, 95% CI 1.11–1.91), alcohol abuse (HR =1.59, 95% CI 1.08–2.35), rheumatic disease (HR =1.40, 95% CI 1.07–1.83), and exposure to drugs with dynamic interaction mechanism with warfarin (HR =1.43, 95% CI 1.20–1.71). In age-adjusted models, Charlson comorbidity index and number of drugs predicted a graded increase in the hazard of early bleeding. CONCLUSION: The rate of hospitalizations for bleeding peaked in the beginning of warfarin therapy. Early bleeders were characterized by venous thrombosis, pulmonary embolism, and factors that increase bleeding risk without affecting the international normalized ratio. Dove Medical Press 2016-02-05 /pmc/articles/PMC4751892/ /pubmed/26917975 http://dx.doi.org/10.2147/CLEP.S91379 Text en © 2016 Rikala et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Rikala, Maria
Kastarinen, Helena
Tiittanen, Pekka
Huupponen, Risto
Korhonen, Maarit Jaana
Natural history of bleeding and characteristics of early bleeders among warfarin initiators – a cohort study in Finland
title Natural history of bleeding and characteristics of early bleeders among warfarin initiators – a cohort study in Finland
title_full Natural history of bleeding and characteristics of early bleeders among warfarin initiators – a cohort study in Finland
title_fullStr Natural history of bleeding and characteristics of early bleeders among warfarin initiators – a cohort study in Finland
title_full_unstemmed Natural history of bleeding and characteristics of early bleeders among warfarin initiators – a cohort study in Finland
title_short Natural history of bleeding and characteristics of early bleeders among warfarin initiators – a cohort study in Finland
title_sort natural history of bleeding and characteristics of early bleeders among warfarin initiators – a cohort study in finland
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4751892/
https://www.ncbi.nlm.nih.gov/pubmed/26917975
http://dx.doi.org/10.2147/CLEP.S91379
work_keys_str_mv AT rikalamaria naturalhistoryofbleedingandcharacteristicsofearlybleedersamongwarfarininitiatorsacohortstudyinfinland
AT kastarinenhelena naturalhistoryofbleedingandcharacteristicsofearlybleedersamongwarfarininitiatorsacohortstudyinfinland
AT tiittanenpekka naturalhistoryofbleedingandcharacteristicsofearlybleedersamongwarfarininitiatorsacohortstudyinfinland
AT huupponenristo naturalhistoryofbleedingandcharacteristicsofearlybleedersamongwarfarininitiatorsacohortstudyinfinland
AT korhonenmaaritjaana naturalhistoryofbleedingandcharacteristicsofearlybleedersamongwarfarininitiatorsacohortstudyinfinland